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Introduction
The diterpenoid salvinorin A is a natural product with 
hallucinogenic properties (Valdes et al., 1983). It has 
been isolated from Mexican sage Salvia divinorum 
Epling & Játiva-M (Labiatae), the only known hallucino-
genic species of the Salvia genus. Salvinorin A attracted 
interest after Roth and co-workers (2002) reported that 
it is a selective and highly potent naturally occurring 
-opioid receptor agonist. It has become a lead com-
pound in searches for new drugs to combat psychiatric 
disorders such as schizophrenia, or Alzheimer’s or other 
dementias, in which -opioid receptors are believed to 
be involved (Sheffler & Roth, 2003). In experiments with 
monkeys addicted to cocaine, -opioid agonists reduce 
cocaine craving (Mello & Negus, 2000). Recent results 
show that salvinorin A, when given to rats along with 
cocaine, attenuates cocaine-induced locomotor activity 
(Chartoff et al., 2008).
The in vivo metabolism of salvinorin A is not fully 
understood (Babu et al., 2008). Although studies 
with isolated body fluids from primates and humans 
incubated with salvinorin A revealed salvinorin B as 
a metabolite (Schmidt et al., 2005b), in vivo pharma-
cokinetic experiments with nonhuman primates failed 
to detect salvinorin B or any other metabolite in the 
bloodstream (Schmidt et al., 2005a). Prompted by 
these conflicting observations, we undertook studies 
of the fungal transformation and ex vivo metabolism 
with salvinorin A.
Smith and Rosazza were the first to propose microbes 
(fungi) as a model for mammalian metabolism (Sebek, 
1982). Metabolites from fermentation are similar to 
those released in phase I (functionalization), or more 
rarely phase II (conjugation), of xenobiotic modifica-
tion by mammalian enzymes (Abourashed et al., 1999; 
Hanson, 1992). Microbial transformation of organic 
compounds is also a convenient method of obtaining 
structurally novel leads for drug discovery. The classes 
of chemicals being enzymatically modified range from 
simple monoterpenoids (Miyazawa et al., 2003), ses-
quiterpenoids (artemisinin) (Parshikov et al., 2006), and 
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Microbial transformation of natural products is a well established model for mammalian metabolism. 
Salvinorin A, a diterpenoid isolated from the hallucinogenic mint Salvia divinorum Epling & Játiva-M 
(Lamiaceae), is a potent non-nitrogenous κ-opioid receptor agonist. The metabolism of salvinorin A has still 
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organelles show that the primary route of salvinorin A metabolism is hydrolysis to salvinorin B. No meta-
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aromatic compounds (Orabi et al., 1999) to structurally 
more complex molecules, such as alkaloids (mor-
phine) (Stabler et al., 2001), higher terpenoids, anti-
biotics, or marine natural products (e.g., sarcophine) 
(El Sayed et al., 1998). ent-Kaurenes and gibbererellins 
are among the most studied terpenoids utilizing micro-
bial systems (Hanson, 1992). Xenobiotic inactivation in 
mammalian systems usually occurs in the liver, where 
hydroxylation, reduction, oxidation, or hydrolysis leads 
to increased polarity of compounds for better water 
solubility and eventual excretion (Venisetty & Ciddi, 
2003). The brain is also a place of drug metabolism, 
where efflux pumps effectively remove drugs from its 
space. For these reasons our ex vivo studies focused on 
these organs.
The goal of this study was to find the metabolites of 
salvinorin A using an analytical model for mammalian 
metabolism. Classical methods of searching for drug 
metabolites such as tracking down the radioactive label, 
or analysis of urine and other body fluids, still suffer 
from several constraints. In this case, one of them is lack 
of appropriately radiolabeled salvinorin A, still a chal-
lenging problem. The potency and unknown side effects 
of this psychedelic agent also limit the amounts that can 
be administered to animals or human volunteers, mak-
ing a search for metabolites difficult. We are reporting 
here microbial transformation as a potential method of 
identifying salvinorin A metabolites.
Materials and methods
General experimental procedures
Mass spectra of crude extracts were generated by 
liquid chromatography-mass spectrometry (LC-MS) 
(Bruker Daltonik microTOF; Leipzig, Germany). 
Analysis was performed using a 150 × 4. 6 mm C8 col-
umn (Phenomenex Luna; Torrance, CA) with 3 m 
particle size and a linear gradient ranging from 20% of 
MeCN to 100% over 20 min. The spectrometer was fur-
nished with a photodiode array detector (Agilent 1100; 
Palo Alto, CA). Positive ionization mode was used in 
high-resolution electrospray ionization (HR-ESI)-MS 
analysis. Nuclear magenetic resonance (NMR) spectra 
were recorded on a 600 MHz Varian Innova instrument 
with a  3 mm Nalorac dual broadband probe. The NMR 
sample of salvinorin B was dissolved in acetonitrile-
d
3
. Chemical shifts were calibrated to residual solvent 
resonances. NMR resonance assignments of salvinorin 
B were according to Giner et al. (2007). Thin layer chro-
matography (TLC) of transformation products was 
performed with Merck HF
254
 silica gel plates, developed 
using a mobile phase composed of hexanes and ethyl 
acetate 1:1, v/v, and visualized by dipping in a 10% 
solution of vanillin–sulfuric acid reagent (1 g of vanillin 
in 40 mL of EtOH and 0.5 mL of conc. H
2
SO
4
), followed 
by heating at 120°C.
Chemicals
All chemicals were purchased from Fisher Scientific 
except for Difco potato dextrose broth (Becton, 
Dickinson and Co., Sparks, MD). Salvia divinorum was 
purchased from the Salvia divinorum Research Center, 
Malibu, CA, USA, and deposited in the Department 
of Pharmacognosy plant repository (voucher speci-
men number FH4-408-07). Crude plant extract was 
obtained through exhaustive extraction of 500 g of dry 
plant material with 6000 mL of acetone (3 × 2000 mL). 
Solvent was removed in vacuo at 35°C and reconsti-
tuted in ethanol for subsequent crystallization. After 
24 h, crystals were filtered and washed with hexane to 
yield 95% pure salvinorin A. Salvinorin B was prepared 
as described elsewhere (Chavkin et al., 2004). Briefly, 
1 g of salvinorin A was dissolved in 500 mL of MeOH, 
1 g of K
2
CO
3
 was added, and the mixture was stirred for 
36 h at room temperature. The precipitate of 95% pure 
salvinorin B was then filtered and dried under vacuum 
for further use.
Chromatographic conditions
Residues obtained from liquid extraction of micro-
bial cultures were dissolved in acetonitrile (MeCN) 
and filtered through a 0.2 µm high-performance 
liquid chromatography (HPLC) filter (Millex-GN; 
Bedford, MA) prior to analysis. Analytical profiling of 
extracts was performed using HPLC (Waters Alliance; 
Waters Corp., Milford, MA) furnished with a Synergi 
Fusion-RP C18 column (150 × 10 mm, 4 µm particle 
size) (Phenomenex). The mobile phase composition 
consisted of phase A – MeCN, and phase B – water. The 
gradient started at 20% of phase A and increased to 80% 
over 30 min, and further to 100% of MeCN in the next 
10 min, followed by 10 min of wash with 100% MeCN. 
Salvinorin A retention time was 20.7 min and salvinorin B 
15.6 min. Isolation of metabolites was performed also 
by HPLC, where the crude extract was loaded onto a 
Phenomenex C8 (250 × 10 mm, 5 µm particle size) col-
umn connected to an HPLC (Delta Prep 4000; Waters 
Corp.) system equipped with a dual wavelength detec-
tor (Model 2487; Waters Corp.). The mobile phase com-
position consisted of an MeCN:H
2
O (40:60) isocratic 
system. Retention time for salvinorin A was 11.3 min 
and salvinorin B 4.1 min. For detection, ultraviolet (UV) 
radiation,  = 210 and 254 nm, was used. For analy-
sis of extracts from ex vivo experiments, a Waters C18 
XTerra column (100 × 7. 6 mm, 5 m particle size) was 
used, where salvinorin A and B retention times were 
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16.3 min and 12.9 min, respectively. The mobile phase 
composition was the same as for the analytical method 
presented above.
Microorganisms
The following fungal strains were chosen for the prelimi-
nary screening and were purchased from the American 
Type Culture Collection (ATCC, Rockville, MD): Mucor 
plumbeus ATCC 8773, Aspergillus niger ATCC 9142, 
Aspergillus flavus ATCC 9170, Cunninghamella bain-
ieri ATCC 9244, Cunninghamella echinulata ATCC 
9245, Mucor ramannianus ATCC 9628, Saccharomyces 
cerevisiae ATCC 9763, Rhizopus oryzae ATCC 11145, 
Rhodococcus rhodochrous ATCC 12674, Fusarium 
solani ATCC 12823, Beauveria bassiana ATCC 13144, 
Mortierella zonata ATCC 13309, Curvularia lunata 
ATCC 13633, Rhizopus stolonifer ATCC 14037, Aspergillus 
niger ATCC 16888, Aspergillus ochraceus ATCC 18412, 
Aspergillus ochraceus ATCC 18500, Mucor mucedo ATCC 
20094, Rhodotorula mucilaginosa ATCC 20129, Absidia 
glauca ATCC 22752, Aspergillus ochraceus ATCC 22947, 
Rhizopus stolonifer ATCC 24795, Verticillium lecanii 
ATCC 28300, Rhizopus oryzae ATCC 34121, Curvularia 
lunata ATCC 34690, Cunninghamella echinulata ATCC 
36190, Cunninghamella echinulata ATCC 10028b, 
Cunninghamella echinulata ATCC 11585a, Rhizopus stol-
onifer ATCC 6227a, and Rhizopus stolonifer ATCC 6227b.
Microbial transformation screening and scale-up
For all stages of fermentation the same medium con-
taining: peptone, yeast extract, potassium phosphate, 
sodium chloride, and dextrose in weight ratio 1:1:1:1:4 
dissolved in double deionized water was used, and the 
pH was adjusted to 7.2 by the addition of 0.1 M potassium 
hydroxide. Medium was autoclaved at 121°C for 15 min. 
Cultures were grown according to the standard two-stage 
procedure (Abourashed et al., 1999). Fermentation was 
inoculated to 125 mL conical Bellco Delong steel capped 
flasks containing 25 mL of broth, where the initial stage 
was run for 72 h, followed by transfer to a fresh medium. 
After 1 day of culture, 5 mg of salvinorin A was added, with 
the final concentration 0.25 mg/mL in dimethylsulfoxide 
(DMSO) (stage II). The second stage was allowed to pro-
ceed for 14 days at 28°C on a rotary shaker (C24KC refrig-
erated shaker; New Brunswick Scientific, Edison, NJ) 
at 200 rpm. Control experiments with the same set of 
microorganisms containing vehicle only were conducted 
simultaneously. After 14 days of incubation the culture 
broth was filtered and extracted with ethyl acetate. The 
organic solvent was evaporated in vacuo at 35°C and sam-
ples were later re-dissolved in acetonitrile for analysis. 
Scale-up experiments were performed under the same 
experimental conditions with a 10-fold increase in broth 
volume and substrate content per selected microorgan-
ism. The kinetics of salvinorin A conversion was meas-
ured by sampling 1 mL of culture broth per day, followed 
by extraction with ethyl acetate. The organic extract was 
subsequently injected into an analytical HPLC apparatus 
and the peak area was measured with regard to standard 
curves of salvinorins A and B.
Ex vivo assays
Adult Sprague-Dawley rats (Harlan, 250–300 g), main-
tained in a 12 h light/dark cycle and fed ad libitum, 
were used for the study. The protocol for the study was 
approved by the University of Mississippi Institutional 
Animal Care and Use Committee (IACUC). Rat brain and 
liver were excised upon decapitation. After dissection, the 
tissues were weighed and immediately homogenized in 
ice-cold buffer (10 mM Tris and 0.25 M sucrose, pH 7.2). 
Homogenates were further fractionated by centrifuga-
tion at 1000 × g for 10 min, 10,000 × g for 20 min (Allegra 
25R centrifuge; Beckmann Coulter, Fullerton, CA), and 
100,000 × g for 60 min (Optima Max ultracentrifuge; 
Beckmann Coulter) to obtain fractions of nuclei, mito-
chondria, and microsomes, respectively. Assays were 
carried out with homogenates of each organ or respective 
organelle fractions in 1 mL of 10 mM Tris buffer (150 mM 
NaCl, pH 7.2). Treatment was done in triplicate whereas 
controls were done in duplicate. Treatment samples were 
incubated with 4 L (10 mmol) salvinorin A dissolved in 
DMSO (50 mM stock). Two types of controls were used in 
the study: the first comprised only buffer and salvinorin A 
to evaluate the stability of salvinorin A in blank Tris 
buffer, and the second contained the respective tissue/
organelle fraction and vehicle. The assay was carried 
out for 1 h at 37°C on a rotary shaker (Thermomixer R; 
Eppendorf, Westbury, NY) at 800 rpm. The reaction was 
terminated by centrifugation at 4°C at 10,000 × g for 5 min. 
The supernatant was then collected and stored at −20°C 
for further HPLC analysis.
Salvinorin B
Salvinorin B was isolated as a white solid, HR-MS m/z 
[M + H]+ 391.1518 (calcd for C
21
H
26
O
7
 390.1679); NMR 
spectroscopic data matched those previously published 
(Giner et al., 2007).
Results and discussion
Microbial transformation of salvinorin A
Microorganisms used for the experiment were previ-
ously reported capable of transforming diterpenoids in 
reactions such as hydroxylation, oxidation, reduction, or 
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epoxidation (Hanson, 1992). A preliminary screening 
of salvinorin A (5 mg) showed that most of the micro-
organisms transformed the substrate into salvinorin B 
(Scheme 1). TLC monitoring of the transformation proc-
ess revealed that some microbes were capable of trans-
forming approximately 50% of the substrate within the 
first 24 h after addition of salvinorin A into a medium 
(data not shown). However, the conversion efficiency 
varied between organisms, so, for example, C. lunata, 
M. zonata, R. rhodochrous, M. plumbeus, A. niger, 
C.  bainieri, and R. stolonifer were capable of complete 
hydrolysis of salvinorin A to salvinorin B within 14 days 
of incubation. Approximately 70% of salvinorin A was 
metabolized into salvinorin B by A. glauca, A. ochra-
ceus, and B. bassiana. M. mucedo, M. ramannianus, and 
R. oryzae hydrolyzed approximately 50% of the substrate 
in this time period. By contrast, V. lecanii, C. lunata, and 
C. echinulata poorly transformed salvinorin A (only 
about 10–15% of conversion to salvinorin B) over 14 days 
of incubation.
Scale-up experiments involved four species and 
all were carried out for 14 days: C. bainieri, M. zonata, 
R. stolonifer, and A. glauca, which were chosen based on 
their TLC and analytical HPLC chromatographic profiles. 
LC-MS analysis was performed to confirm the presence 
of salvinorin B in fermentation extracts. HPLC profiles 
of extracts from scale-up experiments showed the exact 
rate of transformation of salvinorin A into salvinorin B. 
C. bainieri converted salvinorin A to salvinorin B in 100% 
yield (Figure 1), and was used later on to determine the 
kinetics of the conversion. The presented data (Figure 2) 
indicate that 50% of salvinorin A was hydrolyzed to 
salvinorin B within 48 h, and that it was almost completely 
converted 6 days after adding substrate to the culture. 
 M. zonata, which also gave 100% conversion of salvinorin 
A to salvinorin B (~45 mg), was used to isolate and iden-
tify the metabolite. NMR spectra of the metabolite were 
in full agreement with published data, and confirmed 
that the obtained product was indeed salvinorin B (Giner 
et al., 2007). R. stolonifer produced salvinorin B in 90% 
yield, but no other products were detected, compar-
ing with the control strains. The preparative yield of A. 
glauca did not correlate with that of the screening scale, 
with only 37% conversion of salvinorin A to salvinorin B.
To make sure that salvinorin B was indeed the final 
product of microbial metabolism, we performed another 
experiment where we incubated all 30 microorgan-
isms that we used to biotransform salvinorin A with 
pure salvinorin B. Attempts to demonstrate further 
transformation of this compound were unsuccessful. 
Scheme 1. Possible routes of hydrolytic transformations of salvinorin A.
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The screening experiment revealed that none of the 30 
species was able to further metabolize salvinorin B. HPLC 
analysis of additional scale-up experiments involving C. 
echinulata and A. glauca confirmed these results. Both 
salvinorin A and salvinorin B proved to be stable in the 
medium with the absence of microorganisms (substrate 
control), ruling out any possibility of medium-influenced 
hydrolysis or decomposition of the substrate.
There has been only one report indicating that 
salvinorin A is rapidly hydrolyzed in vitro to its inac-
tive metabolite, salvinorin B. Schmidt and co-workers 
(2005a) described the formation of salvinorin B within 
monkey plasma incubated with salvinorin A at 37°C. The 
authors reported that within the first 15 min of incuba-
tion, approximately 20% of salvinorin A was converted 
to salvinorin B, where blood esterases were mainly 
responsible for that conversion. They did not observe 
any other metabolites (Schmidt et al., 2005a). Such a 
short presence of salvinorin A under in vitro conditions 
was also confirmed by in vivo experiments conducted by 
Pichini and co-workers (2005). The average recovery of 
salvinorin A from saliva, 1 h post-treatment, was about 
18.0 ng/mL, and about 6.7 ng/mL from urine (n = 2). 
The total amount of salvinorin A extracted from urine 
after that time was about 0.8% of the administered dose 
(0.5 mg). Blood samples were not analyzed in that study 
(Pichini et al., 2005). An in vivo experiment performed 
by Schmidt et al. (2005b) also showed rapid elimina-
tion of salvinorin A in the rhesus monkey, which varied 
with gender. For the male rhesus monkey, the elimina-
tion half-life was 37.9 ± 5.6 min, whereas for the female 
it was much slower, 80.0 ± 13.1 min. In none of these 
in vivo experiments, however, did the authors observe 
the formation of salvinorin B, or any other metabolites 
of salvinorin A. These should have been detectable in 
the analyzed matrices (Pichini et al., 2005; Schmidt et al., 
2005b).
In our experiments we focused on the microbial model 
as that which could potentially reflect a wider variety of 
the phase I enzymes, resembling the situation present 
in more specific organs such as the liver. Although the 
use of a variety of microbial species was aimed to assess 
possible diverse enzymatic catalysis of salvinorin A 
into more oxidized products than salvinorin B, we were 
unable to show such transformations. At this point we 
conclude that rapid decay of the hallucinogenic effect 
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Figure 1. HPLC chromatogram of C. bainieri crude extract (A) and salvinorin B at 15.6 min (B).
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of salvinorin A, after administration, is most probably 
due to a fast and non-specific hydrolysis of the acetate 
group at C-2 to form salvinorin B. Recent experiments 
with 2-methoxymethyl salvinorin B, which has an ether 
instead of an ester bond, shows that its metabolism is 
greatly slowed by the presence of a hydrolysis-resistant 
group at C-2 (Wang et al., 2008).
Ex vivo metabolism of salvinorin A
We carried out ex vivo metabolism studies using rat liver 
crude homogenate. Incubation of salvinorin A with liver 
crude homogenate resulted in complete hydrolysis of 
substrate to salvinorin B. Further fractionation of the 
homogenate to nuclei, mitochondria, and microsomes 
confirmed the same reaction, with 100% conversion 
in all fractions. Incubation of salvinorin A with cytosol 
also gave a similar result. The ubiquity of hydrolases in 
liver tissue gave the expected deacetylation product of 
salvinorin A. While the liver is the primary site of drug 
metabolism in many organisms, we were expecting to 
observe additional routes of metabolism, such as oxida-
tion by cytochrome P450, or conjugation with glucuronic 
acid. However, none of these reactions were detected. 
Brain tissue is also a place of drug metabolism, but unlike 
the liver, it has a different enzyme composition. In our 
experiment, enzymes from brain homogenate metabo-
lized salvinorin A as efficiently as those from the liver. 
The incubation of individual organelles with salvinorin 
A resulted in full hydrolysis to salvinorin B. Incubation 
with the nuclear and mitochondrial fractions as well 
as with microsomes and cytosol gave the same result. 
Although the cytosol is rich in phase II enzymes, we did 
not observe any transformation product of salvinorin A, 
characteristic of phase II metabolism.
There is no noticeable difference in metabolism of 
salvinorin A between brain and liver, two functionally 
distinct tissues. Although both the liver and the brain 
contain enzymes of phase I of drug metabolism (cyto-
chrome P450, epoxyhydrolases, dehydrogenases, vari-
ous types of oxidases, and oxidoreductases), the brain 
has an effective way of removing drugs from its space, for 
example by using the P-glycoprotein efflux pump (Allt & 
Lawrenson, 2000; Cordon-Cardo et al., 1989). Whether 
there is any deposition of salvinorin B in vivo in any of 
the analyzed tissues remains unknown.
Conclusions
In conclusion, we are reporting here that the biotrans-
formation of salvinorin A, using two independent 
models of mammalian metabolism (fungi/rat liver and 
brain), yielded salvinorin B as the same metabolite. 
The metabolite concentration, however, varied between 
the models. While the substrate is more available to free 
enzyme(s) in ex vivo experiments, fungi, on the other 
hand, vary in mechanisms of substrate uptake and 
enzyme composition, which may have affected the rate 
of salvinorin B production. Attempts to demonstrate 
metabolism of salvinorin B did not yield any further 
detectable metabolites in either model. Although micro-
bial transformation in general is a good method of deri-
vatization of natural products, it was of limited utility in 
this case. There is a need for appropriately radiolabeled 
salvinorin A, which would be a highly valuable tool for 
tracking metabolites in in vivo models.
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